Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
NCT ID: NCT03625401
Last Updated: 2020-03-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
55 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-10-04
Study Completion Date
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
NCT03790982
Alzheimer's Disease
UNKNOWN
PHASE2
Study of LM11A-31-BHS in Mild-moderate AD Patients
NCT03069014
Mild to Moderate Alzheimer's Disease
COMPLETED
PHASE1/PHASE2
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
NCT03507790
Mild to Moderate Alzheimer's Disease
COMPLETED
PHASE2
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
NCT04251182
Alzheimer Disease
COMPLETED
PHASE2
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
NCT00663936
Alzheimer's Disease
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 55 subjects are planned to be enrolled for the entire study. Subjects will be randomized on Day 1 via a centralized interactive response technology (IRT) in a 1:2 ratio to receive placebo or 60 mg AD-35. The Data Safety Monitoring Board (DSMB) will review safety information after the first 30 subjects have completed the Day 30 Visit and make any necessary recommendations regarding changes to the conduct of the study.
After the first 6 months of double-blind treatment, subjects initially on placebo will transition to active study drug, and all subjects will receive 60 mg AD-35 for an additional 6 months of open-label treatment.
After the first 6 months of double-blind treatment, subjects initially on placebo will transition to active study drug, and all subjects will receive 60 mg AD-35 for an additional 6 months of open-label treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer Disease, Early Onset
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet; Placebo group: 3 placebo tablets.
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
During the double-blind period, all of the study personnel, including Investigators, site personnel,the Sponsor's staff (eg, clinical research associate \[CRA\]/monitor), and study subjects will be blinded to treatment assignment. Placebo and AD-35 will be identical in appearance and packaging to preserve blinding.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AD-35 60 mg
AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
Group Type
EXPERIMENTAL
AD-35 60mg group
Intervention Type
DRUG
AD-35 60mg QD
Placebo of AD-35 30 mg
Placebo group: 3 placebo tablets
Group Type
PLACEBO_COMPARATOR
Placebo group
Intervention Type
DRUG
Placebo: 3 placebo of AD-35 30mg tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-35 60mg group
AD-35 60mg QD
Intervention Type
DRUG
Placebo group
Placebo: 3 placebo of AD-35 30mg tablets
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects must be diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer's Association (NIA-AA) (2011) criteria.
2. Subjects must have a Mini-Mental State Examination (MMSE) score of ≥15 and ≤26 at screening and baseline.
3. Subjects must have a brain magnetic resonance imaging (MRI) scan that is consistent with a clinical diagnosis of probable AD.
4. Subjects should not have received Aβ-based or tau-based treatment for AD.
5. Subjects who were previously treated with Acetyl cholinesterase inhibitor (AChEI) or memantine, must have been off of the therapy for at least 3 months prior to baseline assessments. Subjects who have been taking AChEI or memantine for ≤7 days may be considered for enrollment in this study.
6. For subjects who are currently receiving other non-excluded prescription or over-the-counter medications that might affect cognitive function (eg, non-anticholinergic antidepressants, atypical antipsychotics, non-benzodiazepine anxiolytics, soporifics, centrally acting anticholinergic antihistamines, centrally acting anticholinergic antispasmodics):
* Treatment must be at a stable dose for ≥1 month prior to randomization and throughout the duration of the study.
* Treatment given intermittently and on a short-term basis must not be administered within 5 half-lives prior to the screening of neurocognitive assessments.
7. Subjects must be male or female between 50 years to 85 years of age (inclusive), at screening.
8. Female subjects must be post-menopausal for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening.
9. Male subjects with partners of reproductive potential must agree to use a reliable means of contraception (eg, minimum condom + spermicide) during the study and 30 days after discontinuing the study drug.
10. Subjects must have a reliable caregiver with contact at least 3 times per week (combination of face to face visits and telephone contact acceptable). The caregiver must be able to oversee the subject's compliance with study drug and participate in the subject's clinical assessment, to provide meaningful input into the NPI, ADCS-ADL, and CIBIC+.
11. Subjects (or subject's legally authorized representatives and their caregivers) must be able to provide informed consent.
12. Subjects (and their caregivers) must be able to read, write, speak, and understand English to ensure compliance with cognitive testing and study visit procedures.
13. Subjects (and their caregivers) must be willing and able to comply with the protocol's requirements.
14. Subjects must weigh between 45 kg and 90 kg (inclusive), at screening.
15. Subjects must be in general good health in the opinion of the Investigator, based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) in triplicate, and clinical laboratory values.
2. Subjects must have a Mini-Mental State Examination (MMSE) score of ≥15 and ≤26 at screening and baseline.
3. Subjects must have a brain magnetic resonance imaging (MRI) scan that is consistent with a clinical diagnosis of probable AD.
4. Subjects should not have received Aβ-based or tau-based treatment for AD.
5. Subjects who were previously treated with Acetyl cholinesterase inhibitor (AChEI) or memantine, must have been off of the therapy for at least 3 months prior to baseline assessments. Subjects who have been taking AChEI or memantine for ≤7 days may be considered for enrollment in this study.
6. For subjects who are currently receiving other non-excluded prescription or over-the-counter medications that might affect cognitive function (eg, non-anticholinergic antidepressants, atypical antipsychotics, non-benzodiazepine anxiolytics, soporifics, centrally acting anticholinergic antihistamines, centrally acting anticholinergic antispasmodics):
* Treatment must be at a stable dose for ≥1 month prior to randomization and throughout the duration of the study.
* Treatment given intermittently and on a short-term basis must not be administered within 5 half-lives prior to the screening of neurocognitive assessments.
7. Subjects must be male or female between 50 years to 85 years of age (inclusive), at screening.
8. Female subjects must be post-menopausal for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening.
9. Male subjects with partners of reproductive potential must agree to use a reliable means of contraception (eg, minimum condom + spermicide) during the study and 30 days after discontinuing the study drug.
10. Subjects must have a reliable caregiver with contact at least 3 times per week (combination of face to face visits and telephone contact acceptable). The caregiver must be able to oversee the subject's compliance with study drug and participate in the subject's clinical assessment, to provide meaningful input into the NPI, ADCS-ADL, and CIBIC+.
11. Subjects (or subject's legally authorized representatives and their caregivers) must be able to provide informed consent.
12. Subjects (and their caregivers) must be able to read, write, speak, and understand English to ensure compliance with cognitive testing and study visit procedures.
13. Subjects (and their caregivers) must be willing and able to comply with the protocol's requirements.
14. Subjects must weigh between 45 kg and 90 kg (inclusive), at screening.
15. Subjects must be in general good health in the opinion of the Investigator, based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) in triplicate, and clinical laboratory values.
Exclusion Criteria
1. Lack of peripheral venous access.
2. Uncorrected impairment of vision or hearing that would preclude the subject from taking tests, or subjects lacking the ability to communicate.
3. Inability to tolerate MRI procedures or contraindication to MRI, including but not limited to MRI incompatible pacemakers; implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips; implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye; other magnetic, electronic, or mechanical implants; or any other clinical history or examination finding that, in the judgment of the Investigator, would pose a potential hazard in combination with MRI.
4. Severe or unstable medical condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to complete the study assessments.
5. History or presence of clinically evident vascular disease potentially affecting the brain (eg, stroke, clinically significant carotid or vertebral stenosis or plaque, aortic aneurysm, intracranial aneurysm, cerebral hemorrhage, arteriovenous malformation).
6. History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma (eg, cerebral contusion).
7. History or presence of intracranial tumor (eg, meningioma, glioma).
8. Presence of infections that affect the brain function or history of infections that resulted in neurologic sequelae (eg, syphilis, neuroborreliosis, viral or bacterial meningitis/encephalitis,human immunodeficiency virus encephalopathy).
9. History or presence of systemic autoimmune disorders potentially causing progressive neurologic disease (eg, multiple sclerosis, lupus erythematosus, anti-phospholipid antibody syndrome, Behçet disease).
10. History or presence of psychiatric disease other than AD that may affect cognition or prevent completion of study procedures, including but not limited to clinically significant major psychiatric disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) (eg, major depression, schizophrenia, bipolar disorder).
• A history of major depression is acceptable if no episode has been reported within the previous 5 years.
11. History or presence of a neurologic disease other than AD that may affect cognition, including but not limited to Parkinson's disease, corticobasal degeneration, dementia with Lewy bodies, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal degeneration, Huntington's disease, normal pressure hydrocephalus, and hypoxia.
12. History of seizures with the exception of childhood febrile seizures.
13. Known or suspected history of alcohol or drug abuse within the previous 5 years (DSM-V criteria).
14. Evidence of malignancies, acute infections, renal failure that requires dialysis, or other unstable medical disease not related to AD that in the Investigator's opinion would preclude subject participation.
• This does not include any cancer (except adequately treated basal or squamous cell skin cancer) that is not being actively treated with anti-cancer drugs or radiotherapy as well as cancers that are considered to have low probability of recurrence (with supporting documentation of this from the treating oncologist, if possible).
15. History or presence of atrial fibrillation that poses a risk for future stroke in the Investigator's judgment.
16. Severe heart disease (history of myocardial infarction, congestive heart disease, history of unstable angina pectoris, clinically significant ECG abnormality) within 6 months prior to screening. Subjects with peripheral arterial disease will not be excluded if they are stable for at least 6 months prior to screening.
17. Clinically significant vital signs, laboratory, or ECG abnormalities (eg, abnormally prolonged or shortened heart rate, clinical significant arrhythmias, corrected QT interval \[QTcF\] \>450 ms) in the Investigator's judgement. ECG abnormalities should be confirmed by Investigator based on the central read results provided by the ECG core laboratory (Medpace Cardiovascular Core Laboratory \[MCCL\]).
18. Subjects must not have an estimated glomerular filtration rate of \<30 mL/min/1.73 m2, at screening.
19. Impaired hepatic function, as indicated by transaminases \>2 times the upper limit of normal or abnormalities in synthetic function tests judged by the Investigator to be clinically significant.
20. Evidence of poorly-controlled diabetes (glycosylated hemoglobin \>8.0%).
21. Presence of superficial siderosis of central nervous system, or \>4 cerebral microhemorrhages, or evidence of a prior cerebral macrohemorrhage as assessed by T2\*-weighted gradient-recalled-echo (GRE) MRI.
22. Presence of significant cerebral vascular pathology as assessed by MRI.
23. Treatment with any investigational agent within 5 half-lives or 4 weeks prior to screening, whichever is longer.
24. Cognitive dysfunction that might be due to past or current medication (eg, chemotherapy, steroids).
25. Treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, or any subject who has been in an Alzheimer Aβ or tau vaccination trial unless known to have received only placebo.
26. Treatment with anticholinergic antidepressants, typical antipsychotics, or barbiturates.
27. Chronic use of opiates, opioids, or benzodiazepines:
• Intermittent short-term use is allowed except within 5 half-lives prior to any neurocognitive assessment.
28. Use or intention to use any medications/products that are cytochrome P450 (CYP)3A4 substrates with narrow therapeutic indexes.
29. Use or intention to use any medications/products that are known to be strong inducers/inhibitors of CYP3A4 within 7 days prior to the first dose and throughout the period of study drug administration.
30. Consumption of grapefruit juice or grapefruit-containing products within 7 days prior to the first dose and throughout the period of study drug administration.
2. Uncorrected impairment of vision or hearing that would preclude the subject from taking tests, or subjects lacking the ability to communicate.
3. Inability to tolerate MRI procedures or contraindication to MRI, including but not limited to MRI incompatible pacemakers; implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips; implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye; other magnetic, electronic, or mechanical implants; or any other clinical history or examination finding that, in the judgment of the Investigator, would pose a potential hazard in combination with MRI.
4. Severe or unstable medical condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to complete the study assessments.
5. History or presence of clinically evident vascular disease potentially affecting the brain (eg, stroke, clinically significant carotid or vertebral stenosis or plaque, aortic aneurysm, intracranial aneurysm, cerebral hemorrhage, arteriovenous malformation).
6. History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma (eg, cerebral contusion).
7. History or presence of intracranial tumor (eg, meningioma, glioma).
8. Presence of infections that affect the brain function or history of infections that resulted in neurologic sequelae (eg, syphilis, neuroborreliosis, viral or bacterial meningitis/encephalitis,human immunodeficiency virus encephalopathy).
9. History or presence of systemic autoimmune disorders potentially causing progressive neurologic disease (eg, multiple sclerosis, lupus erythematosus, anti-phospholipid antibody syndrome, Behçet disease).
10. History or presence of psychiatric disease other than AD that may affect cognition or prevent completion of study procedures, including but not limited to clinically significant major psychiatric disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) (eg, major depression, schizophrenia, bipolar disorder).
• A history of major depression is acceptable if no episode has been reported within the previous 5 years.
11. History or presence of a neurologic disease other than AD that may affect cognition, including but not limited to Parkinson's disease, corticobasal degeneration, dementia with Lewy bodies, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal degeneration, Huntington's disease, normal pressure hydrocephalus, and hypoxia.
12. History of seizures with the exception of childhood febrile seizures.
13. Known or suspected history of alcohol or drug abuse within the previous 5 years (DSM-V criteria).
14. Evidence of malignancies, acute infections, renal failure that requires dialysis, or other unstable medical disease not related to AD that in the Investigator's opinion would preclude subject participation.
• This does not include any cancer (except adequately treated basal or squamous cell skin cancer) that is not being actively treated with anti-cancer drugs or radiotherapy as well as cancers that are considered to have low probability of recurrence (with supporting documentation of this from the treating oncologist, if possible).
15. History or presence of atrial fibrillation that poses a risk for future stroke in the Investigator's judgment.
16. Severe heart disease (history of myocardial infarction, congestive heart disease, history of unstable angina pectoris, clinically significant ECG abnormality) within 6 months prior to screening. Subjects with peripheral arterial disease will not be excluded if they are stable for at least 6 months prior to screening.
17. Clinically significant vital signs, laboratory, or ECG abnormalities (eg, abnormally prolonged or shortened heart rate, clinical significant arrhythmias, corrected QT interval \[QTcF\] \>450 ms) in the Investigator's judgement. ECG abnormalities should be confirmed by Investigator based on the central read results provided by the ECG core laboratory (Medpace Cardiovascular Core Laboratory \[MCCL\]).
18. Subjects must not have an estimated glomerular filtration rate of \<30 mL/min/1.73 m2, at screening.
19. Impaired hepatic function, as indicated by transaminases \>2 times the upper limit of normal or abnormalities in synthetic function tests judged by the Investigator to be clinically significant.
20. Evidence of poorly-controlled diabetes (glycosylated hemoglobin \>8.0%).
21. Presence of superficial siderosis of central nervous system, or \>4 cerebral microhemorrhages, or evidence of a prior cerebral macrohemorrhage as assessed by T2\*-weighted gradient-recalled-echo (GRE) MRI.
22. Presence of significant cerebral vascular pathology as assessed by MRI.
23. Treatment with any investigational agent within 5 half-lives or 4 weeks prior to screening, whichever is longer.
24. Cognitive dysfunction that might be due to past or current medication (eg, chemotherapy, steroids).
25. Treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, or any subject who has been in an Alzheimer Aβ or tau vaccination trial unless known to have received only placebo.
26. Treatment with anticholinergic antidepressants, typical antipsychotics, or barbiturates.
27. Chronic use of opiates, opioids, or benzodiazepines:
• Intermittent short-term use is allowed except within 5 half-lives prior to any neurocognitive assessment.
28. Use or intention to use any medications/products that are cytochrome P450 (CYP)3A4 substrates with narrow therapeutic indexes.
29. Use or intention to use any medications/products that are known to be strong inducers/inhibitors of CYP3A4 within 7 days prior to the first dose and throughout the period of study drug administration.
30. Consumption of grapefruit juice or grapefruit-containing products within 7 days prior to the first dose and throughout the period of study drug administration.
Minimum Eligible Age
50 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medpace, Inc.
INDUSTRY
Sponsor Role
collaborator
Zhejiang Hisun Pharmaceutical Co. Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rentian (Roy) Feng, PhD
Role: STUDY_DIRECTOR
Zhejiang Hisun Pharmaceuticals Co., Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northern California Research
Sacramento, California, United States
Site Status
Pacific Research Network, Inc.
San Diego, California, United States
Site Status
Brain Matters Research
Delray Beach, Florida, United States
Site Status
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida, United States
Site Status
Meridien Research
Maitland, Florida, United States
Site Status
Meridien Research
Spring Hill, Florida, United States
Site Status
NeuroStudies
Decatur, Georgia, United States
Site Status
Alexian Brothers Neurosciences Institute
Elk Grove Village, Illinois, United States
Site Status
Advanced Memory Research Institute of NJ
Toms River, New Jersey, United States
Site Status
Clinilabs, Inc.
New York, New York, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hisun-AD-35-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
NCT00454870
COMPLETED
PHASE2
Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease
NCT02386306
COMPLETED
PHASE1
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
NCT01009255
COMPLETED
PHASE2
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
NCT06840054
NOT_YET_RECRUITING
PHASE2
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
COMPLETED
PHASE2
Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
NCT01908010
COMPLETED
PHASE1
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
NCT01066481
WITHDRAWN
PHASE2
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
NCT00838110
COMPLETED
PHASE3
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
NCT00722046
COMPLETED
PHASE2
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
NCT00842673
COMPLETED
PHASE2
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
NCT06619613
RECRUITING
PHASE1
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
NCT06964230
NOT_YET_RECRUITING
PHASE2/PHASE3
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
NCT03625622
COMPLETED
PHASE2
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
NCT02353598
COMPLETED
PHASE1
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00105547
COMPLETED
PHASE3
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
NCT00257673
COMPLETED
PHASE2
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
NCT04488419
COMPLETED
PHASE2/PHASE3
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
NCT02006654
COMPLETED
PHASE3
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
NCT03352557
TERMINATED
PHASE2
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
NCT06546995
COMPLETED
PHASE1
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572
COMPLETED
PHASE2
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
NCT00006187
TERMINATED
PHASE3
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
NCT01600859
COMPLETED
PHASE1
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
NCT04491006
COMPLETED
PHASE2
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
NCT01350362
COMPLETED
PHASE2